Solid Tumor Panel
Comprehensive genomic profiling for solid tumors — powering precision oncology with a single, tissue-sparing NGS assay.
CNC Path Lab’s Solid Tumor Panel interrogates clinically relevant cancer genes to detect the mutations, copy number changes, and fusions that drive disease — turning complex tumor genomics into clear, actionable insight for personalized treatment decisions.
Comprehensive Genomic Profiling for Solid Tumors
A Solid Tumor Panel is a targeted next-generation sequencing (NGS) assay that simultaneously analyzes a curated set of cancer-associated genes from a single tumor specimen. In one tissue-sparing test, it captures the diverse alterations that drive solid tumors — from lung and colorectal to breast, melanoma, and beyond.
Because solid tumors are molecularly heterogeneous and often harbor several coexisting drivers, comprehensive genomic profiling is essential to accurate diagnosis and treatment. By consolidating single nucleotide variants, indels, copy number changes, and gene fusions into one report, CNC Path Lab conserves precious tissue while accelerating clinically meaningful answers.
Next-generation sequencing sits at the heart of this approach: its high-throughput, deep-coverage design detects even low-frequency variants with confidence, revealing driver mutations, resistance markers, and therapy-defining biomarkers. The result is a genomic foundation for precision medicine — guiding targeted therapy, immunotherapy eligibility, clinical trial matching, and personalized treatment decisions.
- Consolidate SNVs, indels, CNVs, and fusions into a single tissue-sparing assay.
- Detect low-frequency driver and resistance variants with high analytical sensitivity.
- Match patients to targeted therapies, immunotherapy, and open clinical trials.
- Deliver pathologist-reviewed, clinically actionable genomic reports.
Comprehensive Solid Tumor Panel Capabilities
Every clinically relevant class of genomic alteration — detected, quantified, and interpreted within a single high-depth NGS workflow.
CDCap™ Comprehensive Cancer Panel Kit
Hybridization capture-based NGS assay designed to detect SNVs, indels, CNVs, and gene fusions across 641 cancer-associated genes. Integrates important biomarkers including TMB, MSI, and MMR for immunotherapy response prediction and treatment insights. Optimized with UMI technology for enhanced sensitivity in liquid biopsy applications.
CDCap™ Solid Tumor Mid Panel Kit
Uses advanced hybrid capture technology to profile 122 cancer-related genes and detect SNVs, indels, gene fusions, MSI (19 loci), and 219 chemotherapy-associated markers across multiple tumor types.
CDCap™ Solid Tumor HotSpot Panel Kit
A hybrid capture-based NGS panel designed to analyze hotspot mutations across 49 cancer genes, enabling detection of SNVs, indels, CNVs, and gene fusions for comprehensive solid tumor genomic analysis.
CDCap™ Solid Tumor Fusion RNA Panel Kit
Utilizes targeted RNA sequencing technology to analyze 105 genes for gene fusions, mutations, and expression profiles, enabling sensitive fusion detection in solid tumor research applications.
CDCap™ Lung Cancer Panel Kit
A hybrid capture NGS assay designed to detect SNVs, indels, CNVs, and gene fusions across 23 NSCLC driver genes including full exon regions and key fusion regions, supporting comprehensive lung cancer genomic profiling.
CDAmp™ Colorectal/Gastric Cancer Panel
A multiplex PCR-based NGS panel designed to analyze 35 NCCN-recommended genes and detect key driver mutations including SNVs and indels with sensitivity down to 1% VAF for molecular classification and precision oncology research in colorectal cancer, gastric cancer, and GIST studies.
CDAmp™ Glioma Panel Kit
A PCR-based targeted sequencing panel designed to detect important glioma-associated alterations including IDH1/2 mutations, TERT promoter hotspots, BRAF hotspots, and large CNV deletions involving 1p/19q/10q regions. Supports low-input samples and rapid molecular profiling workflows.
CDCap™ HotSpot Panel
A targeted cancer panel designed to detect SNVs, indels, CNVs, and gene fusions across 49 key cancer genes. Suitable for genomic analysis of FFPE tissue and plasma samples.
A Guided Solid Tumor Sequencing Workflow
From sample collection to a comprehensive clinical report, every step is tracked and quality-controlled.
Sample Collection
Tumor tissue or biopsy specimens are received, accessioned, and tracked under controlled, chain-of-custody conditions.
DNA Extraction
Genomic DNA is isolated from FFPE, fresh, or frozen tissue using protocols tuned for maximal yield and purity.
Library Preparation
Sequencing libraries are constructed and barcoded with strict quality control at every checkpoint.
Target Enrichment
Hybridization-based capture enriches the curated cancer gene panel for deep, focused sequencing.
Next-Generation Sequencing
High-throughput parallel sequencing generates deep, uniform coverage across all targeted regions.
Bioinformatics Analysis
Reads are aligned and variants called and annotated through our validated, reproducible pipeline.
Variant Interpretation
Molecular experts classify variants by clinical significance and therapeutic relevance.
Comprehensive Clinical Report
A clear, pathologist-reviewed report is delivered with actionable findings and interpretive context.
Clinical Applications
Genomically informed insight that supports decisions across the precision oncology continuum.
Precision Oncology
Resolve the molecular drivers of each tumor to guide evidence-based, genomically informed treatment decisions.
Personalized Cancer Therapy
Tailor treatment strategies to a patient’s unique tumor genomic profile rather than a one-size-fits-all approach.
Targeted Therapy Selection
Identify actionable alterations that predict response to approved and investigational targeted agents.
Clinical Trial Enrollment
Match patients to biomarker-driven clinical trials by uncovering eligibility-defining genomic alterations.
Biomarker Discovery
Surface and validate candidate biomarkers that advance research and future diagnostic development.
Disease Monitoring
Track molecular changes over the course of disease to inform ongoing management strategies.
Prognostic Assessment
Leverage genomic signatures that refine risk stratification and prognostic evaluation.
Translational Research
Bridge molecular findings and clinical insight to accelerate discovery-to-bedside programs.
Gene Categories Analyzed
Our curated panel spans the functional gene classes that define solid tumor biology and therapeutic opportunity.
Oncogenes
Genes whose activating alterations drive uncontrolled proliferation and represent key therapeutic targets.
Tumor Suppressor Genes
Guardian genes whose loss-of-function removes critical brakes on tumor growth and genome stability.
DNA Repair Genes
Genes governing genome integrity whose defects create vulnerabilities exploitable by targeted therapy.
Cell Cycle Regulation Genes
Regulators of cell division that, when disrupted, enable unchecked tumor cell replication.
Signaling Pathway Genes
Components of oncogenic signaling cascades that shape tumor behavior and treatment response.
Actionable Biomarkers
Alterations linked to approved therapies, immunotherapy eligibility, and clinical decision-making.
From Tumor Genome to
Personalized Treatment
Comprehensive genomic profiling transforms how solid tumors are understood and treated. By revealing the specific alterations driving each tumor, the Solid Tumor Panel helps clinicians move beyond broad, empirical approaches toward therapy matched to a patient’s individual molecular profile.
Each report pairs high-fidelity sequencing data with expert molecular interpretation, connecting genomic findings to targeted therapy options, immunotherapy biomarkers, and relevant clinical trials — so results translate directly into confident, personalized care decisions.
Actionable Genomic Insight
Driver alterations and resistance markers surfaced with clinical context for immediate decision-making.
Immunotherapy Biomarkers
Genomic signals that inform immunotherapy eligibility alongside targeted treatment options.
Expert Interpretation
Molecular pathologists translate complex variant data into clear, guideline-aligned reporting.
Why Choose CNC Path Lab
A trusted molecular diagnostics partner for comprehensive solid tumor genomic profiling and precision oncology.
Advanced NGS Technology
State-of-the-art next-generation sequencing platforms delivering deep, uniform coverage and high-fidelity data.
High Sensitivity & Specificity
Rigorously validated assays that detect low-frequency variants while minimizing false positives.
Molecular Pathology Expertise
An experienced team of molecular scientists and pathologists guiding interpretation and reporting.
Comprehensive Bioinformatics
A robust, quality-controlled analysis pipeline from raw reads to annotated, curated variants.
Actionable Reporting
Clear, guideline-aligned reports that translate complex genomic data into clinical decisions.
Quality-Controlled Workflows
Standardized protocols and multi-stage checkpoints that safeguard integrity from sample to report.
Fast Turnaround Time
Efficient, streamlined workflows that deliver dependable results within clinically meaningful timelines.
Precision Oncology Focus
Deep domain expertise dedicated to advancing personalized, genomically guided cancer care.
From Sample to Scientific Insight
Partner with a world-class precision diagnostics team
From biomarker discovery to AI-powered digital pathology, CNC Path Lab delivers rigorous, translational science that moves your program forward.
Life science innovators
come to CNC Path Lab
Ready to accelerate your clinical program? Our experts are here to help you design and execute the perfect laboratory strategy. Are you ready?